Publications by authors named "Gilbert C Youssef"
Article Synopsis
- Glioblastoma is described as immunologically "cold," making it resistant to solo immune-checkpoint inhibitors (ICI) like pembrolizumab, although neoadjuvant use may improve survival based on prior studies.
- A study involving 25 additional patients analyzed tumor tissue for gene signatures and found that neoadjuvant pembrolizumab led to decreased cancer proliferation genes and increased T-cell activity, indicating a specific response to this treatment.
- Despite observing these molecular changes, the study did not confirm an overall survival benefit from neoadjuvant pembrolizumab, suggesting that some patients may inherently resist ICI and may need additional therapies for effective treatment.
Background: Following surgery, patients with newly diagnosed glioblastoma frequently enter clinical trials. Nuanced risk assessment is warranted to reduce imbalances between study arms. Here, we aimed (I) to analyze the interactive effects of residual tumor with clinical and molecular factors on outcome and (II) to define a postoperative risk assessment tool.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how the use of Next-Generation Sequencing (NGS) affects the management of glioblastoma (GBM) patients at an academic center.
- It found that out of 557 patients with specific GBM types, a significant portion participated in clinical trials and utilized sequencing results for treatment decisions, yet overall survival rates did not differ significantly between trial participants and non-participants.
- The conclusion highlights that even though NGS is crucial for diagnosis, its potential in choosing targeted therapies for GBM remains underexplored, indicating a need for better integration in clinical practice.